CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 33 enrolled
Drug / intervention
B/F/TAFdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06104306
NCT06104306Phase 4Completed
CompareCT.gov

A Phase 4 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral B/F/TAF After Discontinuing Injectable CAB + RPV

Gilead Sciences·interventional·Posted Oct 27, 2023·Updated Feb 11, 2026

In Brief

A Phase 4 clinical trial evaluating B/F/TAF for HIV-1-infection. Completed, enrolled 33 participants across 18 sites in 3 countries.

Detailed Summary

The goal of this clinical study is to learn how safe it is to switch to an oral therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF) from Cabotegravir + Rilpivirine (CAB+RPV) in participants living with virologically suppressed human immunodeficiency virus type 1 (HIV-1), meaning participants with HIV RNA levels below detectable levels. The primary objective of this study is to assess the safety of switching to B/F/TAF in virologically suppressed participants unable/unwilling to continue on CAB+RPV intramuscular (IM) injections or wishing to switch to oral therapy through Week 12.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1-infection
CountriesCanada, France, United States
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedOct 27, 2023
Enrollment StartDec 13, 2023
Primary CompletionJan 29, 2025
Study CompletionApr 23, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.7 years ago

Interventions

B/F/TAFdrug

Tablets administered orally without regard to food